AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. NUVL
  4. [SCHEDULE 13G] Nuvalent, Inc. SEC Filing

[SCHEDULE 13G] Nuvalent, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source:

Stock NUVL logo
Nuvalent, Inc.

NASDAQ:NUVL

NUVL Rankings

#1737 Ranked by Market Cap
N/A Ranked by Dividends

NUVL Latest News

Jul 21, 2025
Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC
Jun 24, 2025
Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
Jun 23, 2025
Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib
Jun 18, 2025
Nuvalent Appoints Christy Oliger to Board of Directors
May 8, 2025
Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results

NUVL Latest SEC Filings

Jul 21, 2025
[8-K] Nuvalent, Inc. Reports Material Event
Jul 17, 2025
[Form 4] Nuvalent, Inc. Insider Trading Activity
Jul 17, 2025
[Form 4] Nuvalent, Inc. Insider Trading Activity
Jul 15, 2025
[144] Nuvalent, Inc. SEC Filing
Jul 11, 2025
[Form 4] Nuvalent, Inc. Insider Trading Activity

NUVL Stock Data

6.07B
62.83M
2.9%
108.09%
7.75%
Biotechnology
Pharmaceutical Preparations
United States
CAMBRIDGE